Wunderman has been selected to launch a consumer campaign for AstraZeneca's Faslodex, a medication that has been approved for use in postmenopausal women with hormone-receptor positive metastatic breast cancer that has progressed following therapy with a hormonal treatment like tamoxifen. Wunderman will handle DTC and DTP relationship marketing efforts aimed at raising awareness in late stage breast cancer patients. A print campaign is slated for summer 2007. In addition to Faslodex, Wunderman currently handles Arimidex and Casodex/Zoladex. All are part of AstraZeneca's oncology catalog.